Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses

Biology of Mood & Anxiety Disorders

Matthew N Hill²  Sachin Patel¹ 

[1] Departments of Psychiatry, and Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, 724B Robinson Research Building, Nashville, TN, USA

[2] Hotchkiss Brain Institute, Departments of Cell Biology & Anatomy and Psychiatry, University of Calgary, 3330 Hospital Drive NW, Calgary AB T2N4N1, Canada

关键词: PTSD;    Depression;    Anxiety;    Stress;    2-AG;    Anandamide;    Endocannabinoid;   

Others  :  791844
DOI  :  10.1186/2045-5380-3-19

 received in 2013-08-03, accepted in 2013-10-04,  发布年份 2013

【 摘 要 】

Accumulating evidence over the past decade has highlighted an important role of the endocannabinoid (eCB) system in the regulation of stress and emotional behavior across divergent species, from rodents to humans. The general findings from this work indicate that the eCB system plays an important role in gating and buffering the stress response, dampening anxiety and regulating mood. Work in rodents has allowed researchers to determine the neural mechanisms mediating this relationship while work in human populations has demonstrated the possible importance of this system in stress-related psychiatric diseases, such as post-traumatic stress disorder, generalized anxiety and major depression. These stress-protective effects of eCB signaling appear to be primarily mediated by their actions within corticolimbic structures, particularly the amygdala and the prefrontal cortex. The aim of this review is to provide an up-to-date discussion of the current level of knowledge in this field, as well as address the current gaps in knowledge and specific areas of research that require attention.

【 授权许可】

   
2013 Hill and Patel; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Katona I, Freund TF: Multiple functions of endocannabinoid signaling in the brain. Annu Rev Neurosci 2012, 35:529-558.
• [2]Atwood BK, Straiker A, Mackie K: CB2: therapeutic target-in-waiting. Prog Neuropsychopharmacol Biol Psychiatry 2012, 38(1):16-20.
• [3]Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M: Endocannabinoid-mediated control of synaptic transmission. Physiological Rev 2009, 89(1):309-380.
• [4]Ahn K, McKinney MK, Cravatt BF: Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 2008, 108(5):1687-1707.
• [5]Gorzalka BB, Hill MN, Hillard CJ: Regulation of endocannabinoid signaling by stress: implications for stress-related affective disorders. Neurosci Biobehav Rev 2008, 32(6):1152-1160.
• [6]Blankman JL, Cravatt BF: Chemical probes of endocannabinoid metabolism. Pharmacol Rev 2013, 65(2):849-871.
• [7]Haller J, Varga B, Ledent C, Barna I, Freund TF: Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. Eur J Neurosci 2004, 19(7):1906-1912.
• [8]Mikics E, Vas J, Aliczki M, Halasz J, Haller J: Interactions between the anxiogenic effects of CB1 gene disruption and 5-HT3 neurotransmission. Behav Pharmacol 2009, 20(3):265-272.
• [9]Jacob W, Yassouridis A, Marsicano G, Monory K, Lutz B, Wotjak CT: Endocannabinoids render exploratory behaviour largely independent of the test aversiveness: role of glutamatergic transmission. Genes Brain Behav 2009, 8(7):685-698.
• [10]Maccarrone M, Valverde O, Barbaccia ML, Castane A, Maldonado R, Ledent C, Parmentier M, Finazzi-Agro A: Age-related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice: Correlation with behaviour. Eur J Neurosci 2002, 15(7):1178-1186.
• [11]Uriguen L, Perez-Rial S, Ledent C, Palomo T, Manzanares J: Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology 2004, 46(7):966-973.
• [12]Hill MN, Hillard CJ, McEwen BS: Alterations in corticolimbic dendritic morphology and emotional behavior in cannabinoid CB1 receptor-deficient mice parallel the effects of chronic stress. Cereb Cortex 2011, 21(9):2056-2064.
• [13]Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O: Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 2002, 159(4):379-387.
• [14]Haller J, Bakos N, Szirmay M, Ledent C, Freund TF: The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 2002, 16(7):1395-1398.
• [15]Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgansberger W, Di Marzo V, et al.: The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002, 418(6897):530-534.
• [16]Rey AA, Purrio M, Viveros MP, Lutz B: Biphasic effects of cannabinoids in anxiety responses: CB1 and GABAB receptors in the balance of GABAergic and glutamatergic neurotransmission. Neuropsychopharmacology 2012, 37(12):2624-2634.
• [17]Dubreucq S, Matias I, Cardinal P, Haring M, Lutz B, Marsicano G, Chaouloff F: Genetic dissection of the role of cannabinoid type-1 receptors in the emotional consequences of repeated social stress in mice. Neuropsychopharmacology 2012, 37(8):1885-1900.
• [18]Navarro M, Hernandez E, Munoz RM, Del Arco I, Villanua MA, Carrera MR, Rodriguez DeFonseca F: Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 1997, 8(2):491-496.
• [19]Patel S, Hillard CJ: Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 2006, 318(1):304-311.
• [20]Arevalo C, De Miguel R, Hernandez-Tristan R: Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacol Biochem Behav 2001, 70(1):123-131.
• [21]Haller J, Varga B, Ledent C, Freund TF: CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav Pharmacol 2004, 15(4):299-304.
• [22]Rodgers RJ, Evans PM, Murphy A: Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naive and plus-maze-experienced mice. Behav Pharmacol 2005, 16(5–6):405-413.
• [23]Gamble-George JC, Conger JR, Hartley ND, Gupta P, Sumislawski JJ, Patel S: Dissociable effects of CB1 receptor blockade on anxiety-like and consummatory behaviors in the novelty-induced hypophagia test in mice. Psychopharmacology (Berl) 2013, 228:401-409.
• [24]Litvin Y, Phan A, Hill MN, Pfaff DW, McEwen BS: CB1 receptor signaling regulates social anxiety and memory. Genes Brain Behav 2013, 12(5):479-489.
• [25]O’Brien LD, Wills KL, Segsworth B, Dashney B, Rock EM, Limebeer CL, Parker LA: Effect of chronic exposure to rimonabant and phytocannabinoids on anxiety-like behavior and saccharin palatability. Pharmacol Biochem Behav 2013, 103(3):597-602.
• [26]Varga B, Kassai F, Gyertyan I: Interactions of CB1 and mGLU5 receptor antagonists in food intake, anxiety and memory models in rats. Pharmacol Biochem Behav 2012, 103(2):425-430.
• [27]Rodgers RJ, Haller J, Halasz J, Mikics E: 'One-trial sensitization’ to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze. Eur J Neurosci 2003, 17(6):1279-1286.
• [28]Degroot A, Nomikos GG: Genetic deletion and pharmacological blockade of CB1 receptors modulates anxiety in the shock-probe burying test. Eur J Neurosci 2004, 20(4):1059-1064.
• [29]Rubio M, Fernandez-Ruiz J, De Miguel R, Maestro B, Michael Walker J, Ramos JA: CB1 receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcohol withdrawal in rats. Neuropharmacology 2008, 54(6):976-988.
• [30]Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A, Giustino A, et al.: Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003, 9(1):76-81.
• [31]Moreira FA, Kaiser N, Monory K, Lutz B: Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by Cb1 receptors. Neuropharmacology 2008, 54(1):141-150.
• [32]Naderi N, Haghparast A, Saber-Tehrani A, Rezaii N, Alizadeh AM, Khani A, Motamedi F: Interaction between cannabinoid compounds and diazepam on anxiety-like behaviour of mice. Pharmacol Biochem Behav 2008, 89(1):64-75.
• [33]Hill MN, Karacabeyli ES, Gorzalka BB: Estrogen recruits the endocannabinoid system to modulate emotionality. Psychoneuroendocrinology 2007, 32(4):350-357.
• [34]Naidu PS, Varvel SA, Ahn K, Cravatt BF, Martin BR, Lichtman AH: Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology (Berl) 2007, 192(1):61-70.
• [35]Busquets-Garcia A, Puighermanal E, Pastor A, de la Torre R, Maldonado R, Ozaita A: Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses. Biol Psychiatry 2011, 70(5):479-486.
• [36]Scherma M, Medalie J, Fratta W, Vadivel SK, Makriyannis A, Piomelli D, Mikics E, Haller J, Yasar S, Tanda G, Goldberg SR: The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology 2008, 54(1):129-140.
• [37]Haller J, Barna I, Barsvari B, Gyimesi Pelczer K, Yasar S, Panlilio LV, Goldberg S: Interactions between environmental aversiveness and the anxiolytic effects of enhanced cannabinoid signaling by FAAH inhibition in rats. Psychopharmacology (Berl) 2009, 204(4):607-616.
• [38]Rossi S, De Chiara V, Musella A, Sacchetti L, Cantarella C, Castelli M, Cavasinni F, Motta C, Studer V, Bernardi G, Cravatt BF, et al.: Preservation of striatal cannabinoid CB1 receptor function correlates with the antianxiety effects of fatty acid amide hydrolase inhibition. Mol Pharmacol 2010, 78(2):260-268.
• [39]Hill MN, Kumar SA, Filipski SB, Iverson M, Stuhr KL, Keith JM, Cravatt BF, Hillard CJ, Chattarji S, McEwen BS: Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure. Mol Psychiatry 2013, 18:1125-1135.
• [40]Kinsey SG, O’Neal ST, Long JZ, Cravatt BF, Lichtman AH: Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay. Pharmacol Biochem Behav 2010, 98(1):21-27.
• [41]Sumislawski JJ, Ramikie TS, Patel S: Reversible gating of endocannabinoid plasticity in the amygdala by chronic stress: a potential role for monoacylglycerol lipase inhibition in the prevention of stress-induced behavioral adaptation. Neuropsychopharmacology 2011, 36(13):2750-2761.
• [42]Aliczki M, Balogh Z, Tulogdi A, Haller J: The temporal dynamics of the effects of monoacylglycerol lipase blockade on locomotion, anxiety, and body temperature. Behav Pharmacol 2012, 23(4):348-357.
• [43]Aliczki M, Zelena D, Mikics E, Varga ZK, Pinter O, Bakos NV, Varga J, Haller J: Monoacylglycerol lipase inhibition-induced changes in plasma corticosterone levels, anxiety and locomotor activity in male CD1 mice. Horm Behav 2013, 63(5):752-758.
• [44]Sciolino NR, Zhou W, Hohmann AG: Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats. Pharmacol Res 2011, 64:226-234.
• [45]Rubino T, Realini N, Castiglioni C, Guidali C, Vigano D, Marras E, Petrosino S, Perletti G, Maccarrone M, Di Marzo V, Parolaro D: Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cereb Cortex 2008, 18(6):1292-1301.
• [46]Dono LM, Currie PJ: The cannabinoid receptor CB1 inverse agonist AM251 potentiates the anxiogenic activity of urocortin I in the basolateral amygdala. Neuropharmacology 2012, 62(1):192-199.
• [47]John CS, Currie PJ: N-arachidonoyl-serotonin in the basolateral amygdala increases anxiolytic behavior in the elevated plus maze. Behav Brain Res 2012, 233(2):382-388.
• [48]Hill MN, McLaughlin RJ, Pan B, Fitzgerald ML, Roberts CJ, Lee TT, Karatsoreos IN, Mackie K, Viau V, Pickel VM, McEwen BS, et al.: Recruitment of prefrontal cortical endocannabinoid signaling by glucocorticoids contributes to termination of the stress response. J Neurosci 2011, 31(29):10506-10515.
• [49]Kiritoshi T, Sun H, Ren W, Stauffer SR, Lindsley CW, Conn PJ, Neugebauer V: Modulation of pyramidal cell output in the medial prefrontal cortex by mGluR5 interacting with CB1. Neuropharmacology 2013, 66:170-178.
• [50]Shin RM, Tully K, Li Y, Cho JH, Higuchi M, Suhara T, Bolshakov VY: Hierarchical order of coexisting pre- and postsynaptic forms of long-term potentiation at synapses in amygdala. Proc Natl Acad Sci U S A 2010, 107(44):19073-19078.
• [51]Azad SC, Eder M, Marsicano G, Lutz B, Zieglgansberger W, Rammes G: Activation of the cannabinoid receptor type 1 decreases glutamatergic and GABAergic synaptic transmission in the lateral amygdala of the mouse. Learn Mem 2003, 10(2):116-128.
• [52]Perra S, Pillolla G, Luchicchi A, Pistis M: Alcohol inhibits spontaneous activity of basolateral amygdala projection neurons in the rat: involvement of the endocannabinoid system. Alcohol Clin Exp Res 2008, 32(3):443-449.
• [53]Huang YC, Wang SJ, Chiou LC, Gean PW: Mediation of amphetamine-induced long-term depression of synaptic transmission by CB1 cannabinoid receptors in the rat amygdala. J Neurosci 2003, 23(32):10311-10320.
• [54]Riebe CJ, Pamplona FA, Kamprath K, Wotjak CT: Fear relief-toward a new conceptual frame work and what endocannabinoids gotta do with it. Neuroscience 2012, 204:159-185.
• [55]Gunduz-Cinar O, Hill MN, McEwan BS, Holmes A: Amygdala FAAH and anandamide: mediating protection and recovery from stress. Trends Pharmacol Sci 2013. In press
• [56]Hill MN, Hillard CJ, Bambico FR, Patel S, Gorzalka BB, Gobbi G: The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants. Trends Pharmacol Sci 2009, 30(9):484-493.
• [57]Gorzalka BB, Hill MN: Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(7):1575-1585.
• [58]Bambico FR, Gobbi G: The cannabinoid CB1 receptor and the endocannabinoid anandamide: possible antidepressant targets. Expert Opin Ther Targets 2008, 12(11):1347-1366.
• [59]Steiner MA, Wanisch K, Monory K, Marsicano G, Borroni E, Bachli H, Holsboer F, Lutz B, Wotjak CT: Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice. Pharmacogenomics J 2008, 8(3):196-208.
• [60]Aso E, Ozaita A, Valdizan EM, Ledent C, Pazos A, Maldonado R, Valverde O: BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice. J Neurochem 2007, 105:565-572.
• [61]Jardinaud F, Crete D, Canestrelli C, Ledent C, Roques BP, Noble F: CB1 receptor knockout mice show similar behavioral modifications to wild-type mice when enkephalin catabolism is inhibited. Brain Res 2005, 1063(1):77-83.
• [62]Steiner MA, Marsicano G, Nestler EJ, Holsboer F, Lutz B, Wotjak CT: Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice. Psychoneuroendocrinology 2008, 33(1):54-67.
• [63]Hill MN, Gorzalka BB: Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? Behav Pharmacol 2005, 16(5–6):333-352.
• [64]Valverde O, Torrens M: CB1 receptor-deficient mice as a model for depression. Neuroscience 2012, 204:193-206.
• [65]Steiner MA, Marsicano G, Wotjak CT, Lutz B: Conditional cannabinoid receptor type 1 mutants reveal neuron subpopulation-specific effects on behavioral and neuroendocrine stress responses. Psychoneuroendocrinology 2008, 33(8):1165-1170.
• [66]Haring M, Grieb M, Monory K, Lutz B, Moreira FA: Cannabinoid CB1 receptor in the modulation of stress coping behavior in mice: the role of serotonin and different forebrain neuronal subpopulations. Neuropharmacology 2013, 65:83-89.
• [67]Shearman LP, Rosko KM, Fleischer R, Wang J, Xu S, Tong XS, Rocha BA: Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav Pharmacol 2003, 14(8):573-582.
• [68]Griebel G, Stemmelin J, Scatton B: Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol Psychiatry 2005, 57(3):261-267.
• [69]Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP, Witkin JM, Nomikos GG: The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol 2003, 138(4):544-553.
• [70]Adamczyk P, Golda A, McCreary AC, Filip M, Przegalinski E: Activation of endocannabinoid transmission induces antidepressant-like effects in rats. J Physiol Pharmacol 2008, 59(2):217-228.
• [71]Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, Cassano T, Morgese MG, Debonnel G, Duranti A, Tontini A, et al.: Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A 2005, 102(51):18620-18625.
• [72]Hill MN, Gorzalka BB: Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur Neuropsychopharmacol 2005, 15(6):593-599.
• [73]Gobshtis N, Ben-Shabat S, Fride E: Antidepressant-induced undesirable weight gain: prevention with rimonabant without interference with behavioral effectiveness. Eur J Pharmacol 2007, 554(2–3):155-163.
• [74]Beyer CE, Dwyer JM, Piesla MJ, Platt BJ, Shen R, Rahman Z, Chan K, Manners MT, Samad TA, Kennedy JD, Bingham B, et al.: Depression-like phenotype following chronic CB1 receptor antagonism. Neurobiol Dis 2010, 39(2):148-155.
• [75]Bambico FR, Cassano T, Dominguez-Lopez S, Katz N, Walker CD, Piomelli D, Gobbi G: Genetic deletion of fatty acid amide hydrolase alters emotional behavior and serotonergic transmission in the dorsal raphe, prefrontal cortex, and hippocampus. Neuropsychopharmacology 2010, 35(10):2083-2100.
• [76]McLaughlin RJ, Hill MN, Bambico FR, Stuhr KL, Gobbi G, Hillard CJ, Gorzalka BB: Prefrontal cortical anandamide signaling coordinates coping responses to stress through a serotonergic pathway. Eur Neuropsychopharmacol 2012, 22(9):664-671.
• [77]Bambico FR, Katz N, Debonnel G, Gobbi G: Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J Neurosci 2007, 27(43):11700-11711.
• [78]Fride E, Suris R, Weidenfeld J, Mechoulam R: Differential response to acute and repeated stress in cannabinoid CB1 receptor knockout newborn and adult mice. Behav Pharmacol 2005, 16(5–6):431-440.
• [79]Dubreucq S, Kambire S, Conforzi M, Metna-Laurent M, Cannich A, Soria-Gomez E, Richard E, Marsicano G, Chaouloff F: Cannabinoid type 1 receptors located on single-minded 1-expressing neurons control emotional behaviors. Neuroscience 2012, 204:230-244.
• [80]Racz I, Bilkei-Gorzo A, Toth ZE, Michel K, Palkovits M, Zimmer A: A critical role for the cannabinoid CB1 receptors in alcohol dependence and stress-stimulated ethanol drinking. J Neurosci 2003, 23(6):2453-2458.
• [81]Patel S, Roelke CT, Rademacher DJ, Hillard CJ: Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. Eur J Neurosci 2005, 21(4):1057-1069.
• [82]Rademacher DJ, Hillard CJ: Interactions between endocannabinoids and stress-induced decreased sensitivity to natural reward. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31(3):633-641.
• [83]Hill MN, Carrier EJ, McLaughlin RJ, Morrish AC, Meier SE, Hillard CJ, Gorzalka BB: Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. J Neurochem 2008, 106(6):2322-2336.
• [84]Rademacher DJ, Meier SE, Shi L, Ho WS, Jarrahian A, Hillard CJ: Effects of acute and repeated restraint stress on endocannabinoid content in the amygdala, ventral striatum, and medial prefrontal cortex in mice. Neuropharmacology 2008, 54(1):108-116.
• [85]Hill MN, McLaughlin RJ, Morrish AC, Viau V, Floresco SB, Hillard CJ, Gorzalka BB: Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology 2009, 34(13):2733-2745.
• [86]Hill MN, McLaughlin RJ, Bingham B, Shrestha L, Lee TT, Gray JM, Hillard CJ, Gorzalka BB, Viau V: Endogenous cannabinoid signaling is essential for stress adaptation. Proc Natl Acad Sci U S A 2010, 107(20):9406-9411.
• [87]Patel S, Roelke CT, Rademacher DJ, Cullinan WE, Hillard CJ: Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 2004, 145(12):5431-5438.
• [88]Patel S, Kingsley PJ, Mackie K, Marnett LJ, Winder DG: Repeated homotypic stress elevates 2-arachidonoylglycerol levels and enhances short-term endocannabinoid signaling at inhibitory synapses in basolateral amygdala. Neuropsychopharmacology 2009, 34(13):2699-2709.
• [89]Hill MN, Patel S, Carrier EJ, Rademacher DJ, Ormerod BK, Hillard CJ, Gorzalka BB: Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 2005, 30(3):508-515.
• [90]Hill MN, Ho WS, Meier SE, Gorzalka BB, Hillard CJ: Chronic corticosterone treatment increases the endocannabinoid 2-arachidonylglycerol in the rat amygdala. Eur J Pharmacol 2005, 528(1–3):99-102.
• [91]Bortolato M, Mangieri RA, Fu J, Kim JH, Arguello O, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D: Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 2007, 62(10):1103-1110.
• [92]Jiang W, Zhang Y, Xiao L, Van Cleemput J, Ji SP, Bai G, Zhang X: Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest 2005, 115(11):3104-3116.
• [93]Hill MN, Kambo JS, Sun JC, Gorzalka BB, Galea LA: Endocannabinoids modulate stress-induced suppression of hippocampal cell proliferation and activation of defensive behaviours. Eur J Neurosci 2006, 24(7):1845-1849.
• [94]Halikas JA, Goodwin DW, Guze SB: Marihuana effects. a survey of regular users. JAMA 1971, 217(5):692-694.
• [95]Fabre LF, McLendon D: The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety. J Clin Pharmacol 1981, 21(8–9 Suppl):377S-382S.
• [96]Fraser GA: The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther 2009, 15(1):84-88.
• [97]Phan KL, Angstadt M, Golden J, Onyewuenyi I, Popovska A, De Wit H: Cannabinoid modulation of amygdala reactivity to social signals of threat in humans. J Neurosci 2008, 28(10):2313-2319.
• [98]Cornelius JR, Aizenstein HJ, Hariri AR: Amygdala reactivity is inversely related to level of cannabis use in individuals with comorbid cannabis dependence and major depression. Addict Behav 2010, 35(6):644-646.
• [99]Gruber SA, Rogowska J, Yurgelun-Todd DA: Altered affective response in marijuana smokers: An FMRI study. Drug Alcohol Depend 2009, 105(1–2):139-153.
• [100]O’Leary DS, Block RI, Koeppel JA, Flaum M, Schultz SK, Andreasen NC, Ponto LB, Watkins GL, Hurtig RR, Hichwa RD: Effects of smoking marijuana on brain perfusion and cognition. Neuropsychopharmacology 2002, 26(6):802-816.
• [101]Hill MN, Gorzalka BB: Impairments in endocannabinoid signaling and depressive illness. JAMA 2009, 301(11):1165-1166.
• [102]Mitchell PB, Morris MJ: Depression and anxiety with rimonabant. Lancet 2007, 370(9600):1671-1672.
• [103]Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A: Efficacy and safety of the weight-loss drug rimonabant: A meta-analysis of randomised trials. Lancet 2007, 370(9600):1706-1713.
• [104]Topol EJ, Bousser MG, Fox KA, Creager MA, Despres JP, Easton JD, Hamm CW, Montalescot G, Steg PG, Pearson TA, Cohen E, et al.: Rimonabant for prevention of cardiovascular events (crescendo): A randomised, multicentre, placebo-controlled trial. Lancet 2010, 376(9740):517-523.
• [105]De Mattos VB, Prais HA, Daker MV: Melancholic features related to rimonabant. Gen Hosp Psychiatry 2009, 31(6):583-585.
• [106]Goodwin RS, Baumann MH, Gorelick DA, Schwilke E, Schwope DM, Darwin WD, Kelly DL, Schroeder JR, Ortemann-Renon C, Bonnet D, Huestis MA: CB1 - cannabinoid receptor antagonist effects on cortisol in cannabis-dependent men. Am J Drug Alcohol Abuse 2012, 38(1):114-119.
• [107]Horder J, Harmer CJ, Cowen PJ, McCabe C: Reduced neural response to reward following 7 days treatment with the cannabinoid CB1 antagonist rimonabant in healthy volunteers. Int J Neuropsychopharmacol 2010, 13(8):1103-1113.
• [108]Horder J, Cowen PJ, Di Simplicio M, Browning M, Harmer CJ: Acute administration of the cannabinoid CB1 antagonist rimonabant impairs positive affective memory in healthy volunteers. Psychopharmacology (Berl) 2009, 205(1):85-91.
• [109]Horder J, Browning M, Di Simplicio M, Cowen PJ, Harmer CJ: Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing. J Psychopharmacol 2012, 26(1):125-132.
• [110]Hill MN, Miller GE, Carrier EJ, Gorzalka BB, Hillard CJ: Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology 2009, 34(8):1257-1262.
• [111]Chouker A, Kaufmann I, Kreth S, Hauer D, Feuerecker M, Thieme D, Vogeser M, Thiel M, Schelling G: Motion sickness, stress and the endocannabinoid system. PLoS One 2010, 5(5):e10752.
• [112]Dlugos A, Childs E, Stuhr KL, Hillard CJ, De Wit H: Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans. Neuropsychopharmacology 2012, 37(11):2416-2427.
• [113]Hill MN, Miller GE, Ho WS, Gorzalka BB, Hillard CJ: Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry 2008, 41(2):48-53.
• [114]Hauer D, Weis F, Campolongo P, Schopp M, Beiras-Fernandez A, Strewe C, Giehl M, Toth R, Kilger E, Schelling G: Glucocorticoid-endocannabinoid interaction in cardiac surgical patients: relationship to early cognitive dysfunction and late depression. Rev Neurosci 2012, 23(5–6):681-690.
• [115]Neumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng MQ, Gujarro-Anton A, Potenza MN, Bailey CR, Lin SF, Najafzadeh S, Ropchan J, Henry S, Corsi-Travali S, Carson RE, Huang Y: Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry 2013, 18:1034-1040.
• [116]Hill MN, Bierer LM, Makotkine I, Golier JA, Galea S, McEwen BS, Hillard CJ, Yehuda R: Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the world trade center attacks. Psychoneuroendocrinology 2013. doi:pii: S0306-4530(13)00292-8
• [117]Hauer D, Schelling G, Gola H, Campolongo P, Morath J, Roozendaal B, Hamuni G, Karabatsiakis A, Atsak P, Vogeser M, Kolassa IT: Plasma concentrations of endocannabinoids and related primary fatty acid amides in patients with post-traumatic stress disorder. PLoS One 2013, 8(5):e62741.
• [118]Agrawal A, Nelson EC, Littlefield AK, Bucholz KK, Degenhardt L, Henders AK, Madden PA, Martin NG, Montgomery GW, Pergadia ML, Sher KJ, et al.: Cannabinoid receptor genotype moderation of the effects of childhood physical abuse on anhedonia and depression. Arch Gen Psychiatry 2012, 69(7):732-740.
• [119]Pearson JF, Fergusson DM, Horwood LJ, Miller AL, Sullivan PF, Youfang LE, Kennedy MA: Increased risk of major depression by childhood abuse is not modified by CNR1 genotype. Am J Med Genet B Neuropsychiatr Genet 2013, 162B(2):224-226.
• [120]Domschke K, Dannlowski U, Ohrmann P, Lawford B, Bauer J, Kugel H, Heindel W, Young R, Morris P, Arolt V, Deckert J, Suslowa T, Baunea BT: Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression. Eur Neuropsychopharmacol 2008, 18(10):751-759.
• [121]Mitjans M, Gasto C, Catalan R, Fananas L, Arias B: Genetic variability in the endocannabinoid system and 12-week clinical response to citalopram treatment: the role of the CNR1, CNR2 and FAAH genes. J Psychopharmacol 2012, 26(10):1391-1398.
• [122]Juhasz G, Chase D, Pegg E, Downey D, Toth ZG, Stones K, Platt H, Mekli K, Payton A, Elliott R, Anderson IM, Deakin JFW: CNR1 gene is associated with high neuroticism and low agreeableness and interacts with recent negative life events to predict current depressive symptoms. Neuropsychopharmacology 2009, 34(8):2019-2027.
• [123]Chakrabarti B, Kent L, Suckling J, Bullmore E, Baron-Cohen S: Variations in the human cannabinoid receptor (CNR1) gene modulate striatal responses to happy faces. Eur J Neurosci 2006, 23(7):1944-1948.
• [124]Hutchison KE, Haughey H, Niculescu M, Schacht J, Kaiser A, Stitzel J, Horton WJ, Filbey F: The incentive salience of alcohol: translating the effects of genetic variant in CNR1. Arch Gen Psychiatry 2008, 65(7):841-850.
• [125]Hirvonen J, Zanotti-Fregonara P, Umhau JC, George DT, Rallis-Frutos D, Lyoo CH, Li CT, Hines CS, Sun H, Terry GE, Morse C, Zoghbi SS, Pike VW, Innis RB, Heilig M: Reduced cannabinoid CB1 receptor binding in alcohol dependence measured with positron emission tomography. Mol Psychiatry 2012, 18:916-921.
• [126]Schacht JP, Hutchison KE, Filbey FM: Associations between cannabinoid receptor-1 (CNR1) variation and hippocampus and amygdala volumes in heavy cannabis users. Neuropsychopharmacology 2012, 37(11):2368-2376.
• [127]Campbell S, Marriott M, Nahmias C, MacQueen GM: Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am J Psychiatry 2004, 161(4):598-607.
• [128]Gilbertson MW, Shenton ME, Ciszewski A, Kasai K, Lasko NB, Orr SP, Pitman RK: Smaller hippocampal volume predicts pathologic vulnerability to psychological trauma. Nat Neurosci 2002, 5(11):1242-1247.
• [129]Galve-Roperh I, Aguado T, Palazuelos J, Guzman M: The endocannabinoid system and neurogenesis in health and disease. Neuroscientist 2007, 13(2):109-114.
• [130]Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, Azad SC, Cascio MG, Gutierrez SO, van der Stelt M, Lopez-Rodriguez ML, Casanova E, Schütz G, Zieglgänsberger W, Di Marzo V, Behl C, Lutz B, et al.: CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003, 302(5642):84-88.
• [131]Lazary J, Lazary A, Gonda X, Benko A, Molnar E, Hunyady L, Juhasz G, Bagdy G: Promoter variants of the cannabinoid receptor 1 gene (CNR1) in interaction with 5-HTTLPR affect the anxious phenotype. Am J Med Genet B Neuropsychiatr Genet 2009, 150B(8):1118-1127.
• [132]Sipe JC, Chiang K, Gerber AL, Beutler E, Cravatt BF: A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci U S A 2002, 99(12):8394-8399.
• [133]Chiang KP, Gerber AL, Sipe JC, Cravatt BF: Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: Evidence for a link between defects in the endocannabinoid system and problem drug use. Hum Mol Genet 2004, 13(18):2113-2119.
• [134]Sipe JC, Scott TM, Murray S, Harismendy O, Simon GM, Cravatt BF, Waalen J: Biomarkers of endocannabinoid system activation in severe obesity. PLoS One 2010, 5(1):e8792.
• [135]Hariri AR, Gorka A, Hyde LW, Kimak M, Halder I, Ducci F, Ferrell RE, Goldman D, Manuck SB: Divergent effects of genetic variation in endocannabinoid signaling on human threat- and reward-related brain function. Biol Psychiatry 2009, 66(1):9-16.
• [136]Gunduz-Cinar O, Macpherson KP, Cinar R, Gamble-George J, Sugden K, Williams B, Godlewski G, Ramikie TS, Gorka AX, Alapafuja SO, Nikas SP, et al.: Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol Psychiatry 2013, 18(7):813-823.
• [137]Conzelmann A, Reif A, Jacob C, Weyers P, Lesch KP, Lutz B, Pauli P: A polymorphism in the gene of the endocannabinoid-degrading enzyme FAAH (FAAH C385A) is associated with emotional-motivational reactivity. Psychopharmacology (Berl) 2012, 224(4):573-579.
• [138]Patel S, Hillard CJ: Adaptations in endocannabinoid signaling in response to repeated homotypic stress: a novel mechanism for stress habituation. Eur J Neurosci 2008, 27(11):2821-2829.